Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.0349 | 1 | 1 |
Treponema pallidum | adenosine deaminase | 0.02 | 0.2991 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.0349 | 1 | 1 |
Mycobacterium ulcerans | dihydroorotate dehydrogenase 2 | 0.0349 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.02 | 0.2991 | 0.5 |
Trypanosoma brucei | dihydroorotate dehydrogenase (fumarate) | 0.0349 | 1 | 0.5 |
Brugia malayi | Adenosine/AMP deaminase family protein | 0.02 | 0.2991 | 0.2991 |
Entamoeba histolytica | adenosine deaminase, putative | 0.02 | 0.2991 | 1 |
Entamoeba histolytica | adenosine deaminase, putative | 0.02 | 0.2991 | 1 |
Mycobacterium tuberculosis | Probable dihydroorotate dehydrogenase PyrD | 0.0349 | 1 | 1 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.0349 | 1 | 1 |
Plasmodium falciparum | dihydroorotate dehydrogenase | 0.0349 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydroorotate dehydrogenase 2 | 0.0349 | 1 | 0.5 |
Mycobacterium leprae | Probable dihydroorotate dehydrogenase PyrD | 0.0349 | 1 | 1 |
Toxoplasma gondii | dihydroorotate dehydrogenase reveal, putative | 0.0349 | 1 | 1 |
Trichomonas vaginalis | adenosine deaminase, putative | 0.02 | 0.2991 | 1 |
Plasmodium vivax | dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.0349 | 1 | 1 |
Trichomonas vaginalis | adenosine deaminase, putative | 0.02 | 0.2991 | 1 |
Schistosoma mansoni | dihydroorotate dehydrogenase | 0.0349 | 1 | 1 |
Echinococcus granulosus | adenosine deaminase | 0.02 | 0.2991 | 1 |
Echinococcus multilocularis | adenosine deaminase | 0.02 | 0.2991 | 1 |
Onchocerca volvulus | Adenosine deaminase homolog | 0.02 | 0.2991 | 0.5 |
Leishmania major | dihydroorotate dehydrogenase | 0.0349 | 1 | 1 |
Trypanosoma cruzi | dihydroorotate dehydrogenase (fumarate), putative | 0.0349 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.